# US 2010/0168014 A1 · Screening method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168014 A1
- Document ID: US20100168014A1
- Status: Published application
- Kind: A1
- Application number: 12/591,105
- Filed: 2009-11-09
- Published: 2010-07-01
- Earliest claimed: 2004-02-09
- Inventors: Takayuki Hida; Tomoko Sekiya; Toru Sawai; Takashi Seiki; Eiki Takahashi; Michiko Kosasa; Kokichi Harada; Toru Arai
- Web page: https://patentgrep.com/patent/US20100168014A1

## CPC

- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/30: for treating abuse or dependence
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present inventors have found that relaxin-3 has a feeding-stimulating activity, a body weight increasing activity, and fat weight increasing activity by intracerebroventricularly administering relaxin-3 to rats and observing the amount of feeding, body weight and fat weight, and so on after the administration. According to the present invention, a polypeptide having useful effects in stimulating feeding, increasing body weight, and fattening; a therapeutic agent containing said polypeptide; a method of screening for a compound, a substance, or a salt thereof which activates or suppresses a receptor of said polypeptide; a kit for said screening; and an agent which comprises a substance which inhibits expression of said polypeptide, such as a feeding-surpressing agent, a therapeutic agent for the treatment of obesity, and a therapeutic agent for the treatment of diabetes.

## Claims

### Claim at position 1

1-52. (canceled)

### Claim 53

A method of screening for a compound which stimulates feeding or a salt thereof, comprising the steps of
(A) contacting a test substance with a relaxin-3 receptor, a cell containing a relaxin-3 receptor, or a membrane fraction of said cell, and
(B) measuring a cell-stimulating activity via the relaxin-3 receptor.

### Claim 54

A method of screening for a compound which stimulates or suppresses feeding or a salt thereof, comprising the step of
(A) contacting relaxin-3, or a salt thereof, and a test substance with a relaxin-3 receptor, a cell which contains a relaxin-3 receptor, or a membrane fraction of said cell.

### Claim 55 (depends on 54)

The method of screening for a compound which stimulates or suppresses feeding or a salt thereof according to claim 54, wherein it comprises the step of
(B) measuring a cell-stimulating activity via the relaxin-3 receptor.

### Claim 56 (depends on 53, 54, 55)

The method of screening according to any one of claims 53 to 55, wherein the relaxin-3 receptor is SALPR.

### Claim 57 (depends on 56)

The method of screening according to claim 56, wherein SALPR is a polypeptide containing the amino acid sequence represented by SEQ ID NO: 4.

### Claim 58

A kit for screening for a compound which stimulates feeding or a salt thereof, comprising the steps of
(A) contacting a test substance with a relaxin-3 receptor, a cell which contains a relaxin-3 receptor, or a membrane fraction of said cell, and
(B) measuring a cell-stimulating activity via the relaxin-3 receptor.

### Claim 59

A kit for screening for a compound which stimulates or suppresses feeding or a salt thereof, comprising the step of
(A) contacting relaxin-3, or a salt thereof, and a test substance with a relaxin-3 receptor, a cell which contains a relaxin-3 receptor, or a membrane fraction of said cell.

### Claim 60 (depends on 59)

The kit for screening for a compound which stimulates or suppresses feeding or a salt thereof according to claim 59, wherein it comprises the step of
(B) measuring a cell-stimulating activity via the relaxin-3 receptor.

### Claim 61 (depends on 58, 59)

The kit for screening according to claim 58, 59, or 60, wherein the relaxin-3 receptor is SALPR or its partial polypeptide.

### Claim 62 (depends on 61)

The kit for screening according to claim 61, wherein SALPR is a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 4.

### Claim 63

A method of recovering feeding and/or body weight gain in a patient having a disease involving reduced feeding and/or weight loss, comprising administering an effective amount of relaxin-3, or a salt thereof, to a patient in need thereof.

### Claim 64

A method of screening for a compound which increases body weight or a salt thereof, comprising the steps of
(A) contacting a test substance with a relaxin-3 receptor, a cell containing a relaxin-3 receptor, or a membrane fraction of said cell, and
(B) measuring a cell-stimulating activity via the relaxin-3 receptor.

### Claim 65

A method of screening for a compound which increases or decreases body weight or a salt thereof, comprising the step of
(A) contacting relaxin-3, or a salt thereof, and a test substance with a relaxin-3 receptor, a cell which contains a relaxin-3 receptor, or a membrane fraction of said cell.

### Claim 66 (depends on 65)

The method of screening for a compound which increases or decreases body weight or a salt thereof according to claim 65, wherein it comprises the step of
(B) measuring a cell-stimulating activity via the relaxin-3 receptor.

### Claim 67 (depends on 64, 65, 66)

The method of screening according to any one of claims 64 to 66, wherein the relaxin-3 receptor is SALPR or it partial polypeptide.

### Claim 68 (depends on 67)

The method of screening according to claim 67, wherein SALPR is a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 4.

### Claim 69

A kit for screening for a compound which increases body weight or a salt thereof, comprising the steps of
(A) contacting a test substance with a relaxin-3 receptor, a cell containing a relaxin-3 receptor, or a membrane fraction of said cell, and
(B) measuring a cell-stimulating activity via the relaxin-3 receptor.

### Claim 70

A kit for screening for a compound which increases or decreases body weight or a salt thereof, comprising the step of
(A) contacting relaxin-3, or a salt thereof, and a test substance with a relaxin-3 receptor, a cell which contains a relaxin-3 receptor, or a membrane fraction of said cell.

### Claim 71 (depends on 70)

The kit for screening for a compound which increases or decreases body weight or a salt thereof according to claim 70, wherein it comprises the step of
(B) measuring a cell-stimulating activity via the relaxin-3 receptor.

### Claim 72 (depends on 69, 70, 71)

The kit for screening according to claim 69, 70 or 71, wherein the relaxin-3 receptor is SALPR or its partial polypeptide.

### Claim 73 (depends on 72)

The kit for screening according to claim 72, wherein SALPR is a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 4.

### Claim 74

A method of screening for a compound involved in the control of obesity or a salt thereof, comprising the steps of
(A) contacting a test substance with a relaxin-3 receptor, a cell comprising a relaxin-3 receptor, or a membrane fraction of said cell, and
(B) measuring a cell-stimulating activity via the relaxin-3 receptor.

### Claim 75

A method of screening for a compound involved in the control of obesity or a salt thereof, comprising the step of
(A) contacting relaxin-3, or a salt thereof, and a test substance with a relaxin-3 receptor, a cell which contains a relaxin-3 receptor, or a membrane fraction of said cell.

### Claim 76 (depends on 75)

The method of screening for a compound involved in the control of obesity or a salt thereof according to claim 75, wherein it comprises the step of
(B) measuring a cell-stimulating activity via the relaxin-3 receptor.

### Claim 77 (depends on 74, 75, 76)

The method of screening according to any one of claims 74 to 76, wherein the relaxin-3 receptor is SALPR or its partial polypeptide.

### Claim 78 (depends on 77)

The method of screening according to claim 77, wherein SALPR is a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 4.

### Claim 79

A kit for screening for a compound involved in the control of obesity or a salt thereof, comprising the steps of
(A) contacting a test substance with a relaxin-3 receptor, a cell containing a relaxin-3 receptor, or a membrane fraction of said cell, and
(B) measuring a cell-stimulating activity via the relaxin-3 receptor.

### Claim 80

A kit for screening for a compound involved in the control of obesity or a salt thereof, comprising the step of
(A) contacting relaxin-3, or a salt thereof, and a test substance with a relaxin-3 receptor, a cell which contains a relaxin-3 receptor, or a membrane fraction of said cell.

### Claim 81 (depends on 80)

The kit for screening for a compound involved in the control of obesity or a salt thereof according to claim 80, wherein it comprises the step of
(B) measuring a cell-stimulating activity via the relaxin-3 receptor.

### Claim 82 (depends on 79, 80, 81)

The method of screening according to any one of claims 79 to 81, wherein the relaxin-3 receptor is SALPR or its partial polypeptide.

### Claim 83 (depends on 82)

The kit for screening according to claim 82, wherein SALPR is a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 4.
